PD-L1-IN-9 

PD-L1-IN-9 is a PD-L1 inhibitor with an IC₅₀ of 110.85 nM. PD-L1-IN-9 has a K_d of 319 nM for human PD-L1 and a K_d of 450 nM for murine PD-L1. PD-L1-IN-9 blocks the PD-1/PD-L1 interaction, restores T cell-mediated anti-tumor immunity, and induces PD-L1 degradation in tumor tissues. PD-L1-IN-9 exhibits anti-tumor activity and can be used in the research of tumors such as melanoma^[1].

PD-L1-IN-9 (Compound Z38) (48 h) shows low cytotoxicity against B16-F10, Jurkat, HepG2, HCT116 and HeLa cell lines, with IC₅₀ values ranging from 28.18 μM to > 40 μM^[1].
PD-L1-IN-9 (1.5625-25 μM; 48 h) induces HepG2 cell death in a dose-dependent manner by reactivating T cells in the HepG2/Jurkat co-culture system^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PD-L1-IN-9 (Compound Z38) (15-30 mg/kg; i.p.; 7 days) inhibits tumor growth in a dose-dependent manner in B16-F10 melanoma-bearing mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

483.56

C₂₉H₂₉N₃O₄

CC1=C(C2=NC(N(C)C=C3CN4CC[C@@H](C(O)=O)C4)=C3C=C2)C=CC=C1C5=CC6=C(OCCO6)C=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang X, et al. Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo. Bioorg Chem. 2026;170:109477.  [Content Brief]